Keine Story von SuperGen, Inc. mehr verpassen.

SuperGen, Inc.

  • 01.07.2004 – 16:11

    SuperGen Submits Application for EMEA Approval of Orathecin

    DUBLIN, California, July 1 (ots/PRNewswire) -- - EuroGen Subsidiary Seeks Centralized Review for Pancreatic Cancer Treatment SuperGen, Inc. (Nasdaq: SUPG) announced today that a Marketing Authorization Application (MAA) seeking approval of Orathecin(TM) (rubitecan) Capsules has been submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). Orathecin is the Company's investigational oral ...